Steroid versus hyaluronic acid injections for hip arthritis
| ISRCTN | ISRCTN04950164 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN04950164 |
| Protocol serial number | N/A |
| Sponsor | Dorset County Hospital NHS Foundation Trust (UK) |
| Funder | Dorset County Hospital NHS foundation Trust (UK) |
- Submission date
- 30/04/2009
- Registration date
- 11/05/2009
- Last edited
- 11/07/2013
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Peter Ward
Scientific
Scientific
Consultant in Orthopaedics
Dorset County Hospital
Dorchester
DT1 2JY
United Kingdom
| Peter.Ward@dchft.nhs.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective randomised single-blind single-centre study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Intraarticular injections for hip osteoarthritis: Steroid versus Hyaluronic acid: a randomised controlled trial |
| Study objectives | Intraarticular hyaluronic acid injections are better than steroid injections for treatment of hip osteoarthritis. 25/06/2013: Please note that this trial was stopped in March 2012 Added 11/07/2013: NRES research summary: http://www.nres.nhs.uk/researchsummaries/?entryid29=151798 |
| Ethics approval(s) | Added 11/07/2013: NRES Committee London - Central, 18/11/2009, 09/H0718/52 |
| Health condition(s) or problem(s) studied | Hip osteoarthritis |
| Intervention | The participants will be randomly allocated to the following two groups: Group 1: Kenalog® (triamcinolone) 80 mg intraarticular injection into hip joint, used once on Day 1. Group 2: Hyaluronic acid 2 ml intraarticular injection into hip joint, used once on Day 1. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Triamcinolone (steroid), hyaluronic acid |
| Primary outcome measure(s) |
The following will be assessed at 6 weeks, 3 and 6 months: |
| Key secondary outcome measure(s) |
1. Duration of pain relief |
| Completion date | 31/12/2010 |
| Reason abandoned (if study stopped) | Lack of funding/sponsorship |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 110 |
| Key inclusion criteria | 1. Clinical and radiological diagnosis of osteoarthritis (primary or secondary) 2. Both males and females, age over 16 years 3. Ability to understand the process and consent |
| Key exclusion criteria | 1. Presence of any active infection elsewhere 2. History of previous hip joint infection 3. Patients with a diagnosis of avascular necrosis of femoral head 4. Rheumatoid arthritis 5. Underlying joint replacement |
| Date of first enrolment | 01/07/2009 |
| Date of final enrolment | 31/12/2010 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Consultant in Orthopaedics
Dorchester
DT1 2JY
United Kingdom
DT1 2JY
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
